Transplantation outcomes: engraftment and GVHD
| . | De novo AML (n = 590) . | sAML (n = 129) . | P . | Overall (N = 719) . |
|---|---|---|---|---|
| Engraftment | ||||
| Graft failure | 66 (11.6%) | 21 (16.5%) | .13 | 87 (12.5%) |
| Engrafted | 502 (88.4%) | 106 (83.5%) | 608 (87.5%) | |
| Missing | 22 | 2 | 24 | |
| Cumulative incidence of PMN > 500 | 88.2% [85.2-90.6] | 83.3% [75.5-88.9] | .042 | |
| aGVHD | ||||
| Grade 1 | 121 (21.3%) | 22 (17.5%) | ND | 143 (20.6%) |
| Grade 2 | 89 (15.7%) | 13 (10.3%) | 102 (14.7%) | |
| Grade 3 | 39 (6.9%) | 5 (4%) | 44 (6.3%) | |
| Grade 4 | 23 (4%) | 7 (5.6%) | 30 (4.3%) | |
| Present, grade unknown | 3 (0.5%) | 1 (0.8%) | 4 (0.6%) | |
| No aGVHD present (grade 0) | 293 (51.6%) | 78 (61.9%) | 371 (53.5%) | |
| Missing | 22 | 3 | 25 |
| . | De novo AML (n = 590) . | sAML (n = 129) . | P . | Overall (N = 719) . |
|---|---|---|---|---|
| Engraftment | ||||
| Graft failure | 66 (11.6%) | 21 (16.5%) | .13 | 87 (12.5%) |
| Engrafted | 502 (88.4%) | 106 (83.5%) | 608 (87.5%) | |
| Missing | 22 | 2 | 24 | |
| Cumulative incidence of PMN > 500 | 88.2% [85.2-90.6] | 83.3% [75.5-88.9] | .042 | |
| aGVHD | ||||
| Grade 1 | 121 (21.3%) | 22 (17.5%) | ND | 143 (20.6%) |
| Grade 2 | 89 (15.7%) | 13 (10.3%) | 102 (14.7%) | |
| Grade 3 | 39 (6.9%) | 5 (4%) | 44 (6.3%) | |
| Grade 4 | 23 (4%) | 7 (5.6%) | 30 (4.3%) | |
| Present, grade unknown | 3 (0.5%) | 1 (0.8%) | 4 (0.6%) | |
| No aGVHD present (grade 0) | 293 (51.6%) | 78 (61.9%) | 371 (53.5%) | |
| Missing | 22 | 3 | 25 |
Unless otherwise stated, results expressed as frequency (%); the numbers are the raw percentages for each grade GVHD.
ND, not done; PMN, polymorphonuclear neutrophils.